Document:

EX-10.28

 Exhibit 10.28 

 
 

 
 October 29, 2018 
 Susan
Stimson 
  

	Re:	 Amended and Restated Employment Terms 

Dear Susan: 
 Intersect ENT, Inc. (the “Company”) is
pleased to offer you the position of Chief Strategy Officer on the following terms. These terms shall supersede and replace, in their entirety, the terms set forth in your most recent offer letter from the Company (which was effective
January 21, 2014) (the “2014 Letter”). 
 You will be responsible for the management and oversight of all aspects of the Company’s
operations and personnel related to market access operations, including reimbursement support, and business development. You will continue to report directly to me, as the Company’s CEO, and you will be based at our offices located in
Menlo Park, California. Of course, subject to your Good Reason rights described below, the Company may change your position, duties, and work location from time to time in its discretion. 

Effective as of October 1, 2018 your base salary will be $325,000 per year, less payroll deductions and all required withholdings. You will be paid every
other Friday and you will be eligible for the Company’s standard benefits, including: health, dental, and vision insurance, paid time off, and holidays (subject to the terms and conditions of such plans). Details about all our benefit plans are
available for your review. 
 In addition, you will also be eligible for an annual bonus of up to 35% of your eligible annual earnings (base salary paid
during the calendar year), less deductions and required withholdings. Your annual bonus will be determined in the sole discretion of the Company based upon an evaluation of both your performance and the Company’s performance, and such other
criteria that the Company deems relevant. Bonuses are earned upon payment. Thus, in order to earn any such bonus, you must remain employed through the time when bonuses are paid in the first quarter after the end of the fiscal year to which the
bonus applies. The Company may change compensation and benefits from time to time in its discretion. As an exempt salaried employee, you will not be eligible for overtime pay. 

You have previously been granted various equity interests in the Company. Except as set forth herein, all such interests shall continue to be governed in all
respects by the terms of the applicable plan documents and option and restricted stock unit agreements. 

 Susan Stimson 

October 29, 2018 
  Page
 2
 
  

 As originally agreed in your 2014 Letter, if you are a full-time employee at the time of the closing of a
Change in Control (as defined below), 50% of the then unvested shares subject to all Company stock options and restricted stock units held by you shall be fully vested. Notwithstanding the foregoing, as a
pre-condition of the accelerated vesting referenced in the immediately preceding sentence, you will be required to timely sign, date and return to the Company (or its successor), and to not subsequently
revoke, a general release of all known and unknown claims in the form provided to you by the Company. 
 If within one month before or within 12 months
after the closing of a Change in Control (as defined below), your employment is either (A) terminated by the Company or a successor entity without Cause (defined below)(and not in connection with death or disability), or (B) terminated by
you due to your resignation for Good Reason (defined below), provided that such termination constitutes a “separation from service” (as defined under Treasury Regulation Section 1.409A-1(h),
without regard to any alternative definition thereunder, a “Separation from Service”), then 100% of the then unvested shares subject to all Company stock options and restricted stock units held by you shall be fully vested. Notwithstanding
the foregoing, as a pre-condition of the accelerated vesting referenced in the immediately preceding sentence, you will be required to timely sign, date and return to the Company (or its successor), and to not
subsequently revoke, a general release of all known and unknown claims in the form provided to you by the Company. 
 In addition, you shall receive the
Severance Benefits (as defined below) if at any time your employment is either (i) terminated by the Company or a successor entity without Cause (defined below) (and not in connection with death or disability), or (ii) terminated by you
due to your resignation for Good Reason (defined below), provided that such termination constitutes a Separation from Service” (as defined above). 

For purposes of this letter agreement, the following definitions shall apply: 

(1) Change in Control. “Change in Control” shall mean the following: (i) any consolidation or merger of the
Company with or into any other corporation or other entity or person, or any other corporate reorganization, other than any such consolidation, merger or reorganization in which the stockholders of the Company immediately prior to such
consolidation, merger or reorganization, continue to hold a majority of the voting power of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation, merger or reorganization;
(ii) any transaction or series of related transactions to which the Company is a party in which in excess of fifty percent (50%) of the Company’s voting power is transferred; provided that the foregoing shall not include any transaction or
series of transactions principally for bona fide equity financing purposes in which cash is received by the Company or indebtedness of the Company is cancelled or converted or a combination thereof; or (iii) a sale, lease, exclusive license or
other disposition of all or substantially all of the assets of the Company. 

 Susan Stimson 

October 29, 2018 
  Page
 3
 
  

 (2) Cause. “Cause” shall mean any of the following conduct by you:
(i) embezzlement, misappropriation of corporate funds, or other material acts of dishonesty; (ii) commission or conviction of any felony, or of any misdemeanor involving moral turpitude, or entry of a plea of guilty or nolo contendere to
any felony or misdemeanor; (iii) engagement in any activity that you know or should know could materially harm the business or reputation of the Company; (iv) material failure to adhere to the Company’s corporate codes, policies or
procedures as in effect from time to time; (v) material violation of any statutory, contractual, or common law duty or obligation to the Company, including, without limitation, the duty of loyalty; (vi) repeated failure, in the reasonable
judgment of the Board, to substantially perform your assigned duties or responsibilities after written notice from the Board describing the failure(s) in reasonable detail and your failure to cure such failure(s) within thirty (30) days of
receiving such written notice; or (vii) material breach of the Company’s Employee Confidential Information and Inventions Agreement executed by you (“Confidential Information Agreement”). 

(3) Good Reason. “Good Reason” shall mean any of the following which occurs without your written consent: (i) a
relocation of the office where you are required to work to a location more than thirty-five (35) miles from the office where you previously were required to work; (ii) a material decrease in your base salary (except for salary decreases
generally applicable to the Company’s other executive employees); or (iii) a material reduction in the scope of your duties or responsibilities, provided, however, that to resign for Good Reason, you must (1) provide written notice to
the Company’s Chief Executive Officer within 30 days after the first occurrence of the event giving rise to Good Reason setting forth the basis for your resignation, (2) allow the Company at least 30 days from receipt of such written
notice to cure such event, and (3) if such event is not reasonably cured within such period, your resignation from all positions you then hold with the Company is effective not later than 90 days after the expiration of the cure period. 

(4) Severance Benefits. “Severance Benefits” shall mean (i) payment of twelve (12) months of your base
salary, less all applicable withholdings and deductions, paid over such 12-month period immediately following the Separation from Service, on the schedule described below (the “Salary Continuation”);
(ii) a lump sum payment equal to your annual target bonus prorated for the number of days of the then current bonus period worked prior to your Separation from Service; and (iii) if you timely elect continued coverage under COBRA, twelve
(12) months COBRA reimbursement (with such reimbursement to cease if you become eligible for health insurance benefits through a new employer). Such Severance Benefits are conditional upon (a) your continuing to comply with your
obligations under your Confidential Information Agreement during the period of time in which you are receiving the Severance Benefits; and (b) your delivering to the Company an effective, general release of claims in favor of the Company in a
form acceptable to the Company within 60 days following your Separation from Service. The Salary Continuation will be paid in equal installments on the Company’s regular payroll schedule and will be subject to applicable tax withholdings over
the period outlined above following the date of your Separation from Service; provided, however, that no payments will be made prior to the 60th day following your Separation from Service. On the 60th day following your Separation from Service, the
Company will pay you in a lump sum the Salary Continuation 

 Susan Stimson 

October 29, 2018 
  Page
 4
 
  

 
and the pro-rated target bonus payment that you would have received on or prior to such date under the original schedule but for the delay while waiting
for the 60th day in compliance with Section 409A of the Internal Revenue Code of 1986, as amended (“Code Section 409A”) and the effectiveness of the release, with the balance of the Salary Continuation being paid as originally
scheduled. 
 As a condition of your employment, you are required to abide by the Company’s policies and procedures. You also agree to read, sign and
comply with the Confidential Information Agreement. 
 In your work for the Company, you will be expected not to make unauthorized use or disclosure of any
confidential information or materials, including trade secrets, of any former employer or other third party to whom you have an obligation of confidentiality. Rather, you will be expected to use only that information generally known and used by
persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the Company. By accepting employment with the Company,
you are representing to us that you will be able to perform your duties within the guidelines described in this paragraph. You represent further that you have disclosed to the Company any contract you have signed that may restrict your activities on
behalf of the Company in any manner. 
 Your employment relationship is at-will. Accordingly, you may terminate your
employment with the Company at any time and for any reason whatsoever simply by notifying the Company. Likewise, the Company may terminate your employment at any time, with or without cause or advance notice. 

It is intended that all of the benefits and payments under this letter satisfy, to the greatest extent possible, the exemptions from the application of Code
Section 409A provided under Treasury Regulations 1.409A 1(b)(4), 1.409A 1(b)(5) and 1.409A 1(b)(9), and this letter will be construed to the greatest extent possible as consistent with those provisions. If not so exempt, this letter (and any
definitions hereunder) will be construed in a manner that complies with Code Section 409A, and incorporates by reference all required definitions and payment terms. For purposes of Code Section 409A (including, without limitation, for
purposes of Treasury Regulation Section 1.409A 2(b)(2)(iii)), your right to receive any installment payments under this letter (whether severance payments, reimbursements or otherwise) will be treated as a right to receive a series of separate
payments and, accordingly, each installment payment hereunder will at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this letter, if you are deemed by the Company at the time of your
Separation from Service to be a “specified employee” for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon your Termination of Services set forth herein and/or under any other agreement with the Company are
deemed to be “deferred compensation”, then if delayed commencement of any portion of such payments is required to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Code
Section 409A, the timing of the payments upon your Separation from Service will be delayed as follows: on the earlier to occur of (i) the date that is six months and one day after the effective date of your Termination of

 Susan Stimson 

October 29, 2018 
  Page
 5
 
  

 
Services, and (ii) the date of the your death (such earlier date, the “Delayed Initial Payment Date”), the Company will (A) pay to you a lump sum amount equal to the sum of
the payments upon your Separation from Service that you would otherwise have received through the Delayed Initial Payment Date if the commencement of the payments had not been delayed pursuant to this paragraph, and (B) commence paying the
balance of the payments in accordance with the applicable payment schedules set forth above. 
 This letter, together with your Confidential Information
Agreement, forms the complete and exclusive statement of your agreement with the Company concerning the subject matter hereof. The terms in this letter supersede any other representations or agreements made to you by any party, whether oral or
written, including without limitation, all of your previous offer letters and agreements describing the terms of your employment with the Company, including the 2014 Letter. The terms of this agreement cannot be changed (except with respect to those
changes expressly reserved to the Company’s discretion in this letter) without a written agreement signed by you and a duly authorized officer of the Company. This agreement is to be governed by the laws of the state of California without
reference to conflicts of law principles. Any action brought by either party under or in relation to this agreement, including without limitation to interpret or enforce any provision of this agreement, shall be brought in, and each party agrees to
and does hereby submit to the jurisdiction and venue of, any state or federal court located in the County of San Mateo, California. In case any provision contained in this agreement shall, for any reason, be held invalid or unenforceable in any
respect, such invalidity or unenforceability shall not affect the other provisions of this agreement, and such provision will be construed and enforced so as to render it valid and enforceable consistent with the general intent of the parties
insofar as possible under applicable law. With respect to the enforcement of this agreement, no waiver of any right hereunder shall be effective unless it is in writing. For purposes of construction of this agreement, any ambiguity shall not be
construed against either party as the drafter. This agreement may be executed in more than one counterpart, and signatures transmitted via facsimile shall be deemed equivalent to originals. As required by law, this offer is subject to satisfactory
proof of your identity and right to work in the United States. 
 You agree that you have been provided with an opportunity to consult with you own counsel
with respect to this agreement. 
 If you wish to accept the revised employment terms described above, please sign and date this letter. The offer
represented hereby shall be valid until October 31, 2018 and upon your acceptance shall be effective as of October 29, 2018 (“Commencement Date”). 

 Susan Stimson 

October 29, 2018 
  Page
 6
 
  

 Congratulations on this new role at the Company. We look forward to continuing our work together. 

Sincerely, 
  

	
	 /s/ Lisa Earnhardt

	Lisa Earnhardt
	Chief Executive Officer

  

					
	Understood and Accepted:	    		  	
			
	 /s/ Susan Stimson
	    	 10/26/2018
	  	
	Susan Stimson	    	DateEX-10.42

 Exhibit 10.42 

 

					
	 Exova
 2395 Speakman Dr.

Mississauga
 Ontario

Canada
 L5K 1B3
	  	 T: + 1 (905) 822-4111

F: + 1 (905) 823-1446
 E:
sales@exova.com
 W: www@exova.com
	  	

 Testing. Calibrating. Advising 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Analytical Testing Partnership Program 2018 - 2020 
  

			
	Quotation to:	  	 Intersect ENT
 1049 Elwell Court

Palo Alto CA 94303
 USA

		
	Attention:	  	 Xiaoyi Hu
 Manager CMC and Analytical
Services
 650-641-2111

xhu@intersectENT.com
  

Rich Kaufman
 Chief Operating Officer

650-641-2107

rkaufman@intersectENT.com

		
	Quotation Number:	  	18-011-541531
		
	Date:	  	April 05, 2018

  

			
	Analytical Testing Partnership Program 2018- 2020	  	Page 2 of 5
	For Intersect ENT	  	Quotation No.: 18-011-541531

  

 

 EXECUTIVE SUMMARY 

Exova’s Health Sciences group has developed a strong relationship with Intersect ENT during the past decade. Over this period, services provided have
included method development, method and process validation, contaminant and unknown Investigation, characterization of Impurities, raw material and finished product testing, and stability program services. 

Intersect ENT has had major success in product development, clinical efficacy and approval of its novel stent products. The company continues to experience
rapid growth and Exova has made Investments to Increase our capacity in tandem, so that Intersect ENT can continue to rely on Exova as the vendor of choice for analytical support and development. We appreciate your regular feedback and this has been
very valuable in making changes and Improvements so that our final product meets your expectations. 
 Exova is committed to working with Intersect ENT to
manage costs and to extend our mutually beneficial and cost effective long term partnership through 2020. 
 We are looking forward to continuing to support
Intersect ENT for analytical testing development and stability needs. 
  

					
	Approved by:	 		  	
			
	 /s/ Eric Lindsay
	 	04.05.18	  	 /s/ John McNelli

	 Eric Lindsay
 General Manager

Health Sciences Santa Fe Springs
	 		  	 John McNelli, M.Sc., C. Chem.
 Director
Pharmaceutical Development
 Health Sciences Americas

 

	
	 /s/ Ben Vanasse

	 Ben Vanasse
 General Manager

Health Sciences Mississauga

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  

			
	Analytical Testing Partnership Program 2018- 2020	  	Page 3 of 5
	For Intersect ENT	  	Quotation No.: 18-011-541531

  

 

 PRICING 

Table 1 
 Custom Analyses
Exova Santa Fe Springs 
  

									
	 Test Method
	  	Price Structure
[*]	 	 	Price Structure
[*]	 
	 [*]
	  	 	[	*] 	 	 	[	*] 

 The pricing indicated in the above table is quoted for [*] turnaround (please note: turnaround time is defined as delivery of
the final Certificate of Analysis by 5:00 PM PT on the day promised). 24 and 72 hour priority service will be accompanied by a surcharge of [*]% and [*]%, respectively. 
  

	 	(1)	 To assist Exova in making compressed timing commitments, Intersect ENT will work to provide pre-notification whenever possible of upcoming sample submission schedules. 

  

	 	(2)	 Raw Data packages are [*]% of the total analytical cost, $[*] minimum and $[*] maximum. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  

			
	Analytical Testing Partnership Program 2018- 2020	  	Page 4 of 5
	For Intersect ENT	  	Quotation No.: 18-011-541531

  

 

 Table 2 

Custom Analyses Exova Mississauga 
  

					
	 Test Method
	  	Price Structure
[*]	 
	 [*]
	  	 	[	*] 

  

	 	(1)	 [*], to ensure that [*] turnaround commitments are consistently met, Intersect ENT will provide [*] forewarning
of upcoming sample submissions and batch samples shipments whenever possible. If [*] requiring [*], timeline should be discussed and agreed upon between Exova and Intersect ENT. When [*] is requested for [*], additional samples will be requested by
Exova and the results available in less than [*] from sample receipt. 

  

	 	(2)	 This test includes [*] as part of the listed fee as this data will be acquired in [*]. 

 

	 	(3)	 No cost for set up will be applied if [*]. If [*], a set up cost of $[*] will be applied.

  

	 	(4)	 The pricing indicated in the above table is quoted for [*] turnaround (turnaround time is defined as delivery
of the final Certificate of Analysis by 5:00 PM PT on the day promised). 

 24 and 72 hour priority service will be
accompanied by a surcharge of [*]% and [*]%, respectively. 

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  

			
	Analytical Testing Partnership Program 2018- 2020	  	Page 5 of 5
	For Intersect ENT	  	Quotation No.: 18-011-541531

  

 

 Table 3 

USP/NF/EP/Custom Monograph Testing 
  

									
	 Test Method
	  	Price Structure
[*]	 	 	Price Structure
[*]	 
	 [*]
	  	 	[	*] 	 	 	[	*] 

  

	*	 Raw Data packages are [*]% of the total analytical cost, $[*] minimum and $[*] maximum. The pricing indicated
in the above table is quoted for [*] turnaround (please note; turnaround time is defined as delivery of the final certificate of analysis by 5:00 PM PT on the day promised). 24 and 72 hour priority service will be accompanied by a surcharge of [*]%
and [*]%, respectively. 

  

	 	(1)	 To ensure that turnaround commitments are consistently met, intersectENT will provide five to ten days
forewarning of upcoming sample submissions and batch sample shipments whenever possible. 

 TERMS AND CONDITIONS 

This quotation is open for acceptance until March 15, 2018, and these prices will be in effect until December 31, 2020. It can be accepted on or
before this date by signing and returning to Exova. At the beginning of 2018, the cost adjustment was applied for year 2018 and [*]% increase will be applied at the beginning of 2019 and 2020. After the validity date, Exova reserves the right to
revise and/or withdraw the quotation as appropriate. This quotation has been prepared exclusively on behalf of Exova and is provided in confidence. The contents of this quotation including pricing information is for the sole consideration of
Intersect ENT and cannot be divulged to a third party without the expressed written consent of Exova. 
 This quotation and the services are governed by the
terms and conditions (“the Conditions”) as attached. This quotation may be accepted by signing the enclosed copy in the space provided below and returning it, for receipt by Exova within the time for acceptance given above. It will then
constitute an agreement between us (the “Contract”). Please be advised that a purchase order is acceptable for billing purposes only, and the work is governed by the attached terms and conditions. 

Accepted by Intersect ENT: 
  

							
	 /s/ NK 
	  	 Richard Kaufman
	  	 Chief Operating Officer
	  	 4/26/18

	Signature	  	Name	  	Title	  	Date

  
 [*] = Certain confidential information
contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]